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Abstract
Calcific aortic valve stenosis is the most common valvular heart disease in developed countries.
Without surgery, the prognosis is extremely dismal. Therefore there is general agreement that
surgical aortic valve replacement should be offered to patients with symptomatic severe aortic
valve stenosis. However, surgery is denied to approx. 30–40% of elderly patients with severe,
symptomatic aortic stenosis due to high perioperative risk. Transcatheter aortic valve implanta-
tion (TAVI) is a novel and effective procedure which provides a promising treatment option for
some of these patients. This review focuses on TAVI systems, the patients who would benefit from
TAVI, and the advantages and disadvantages of the procedure. (Cardiol J 2011; 18, 4: 461–468)
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Calcific aortic valve stenosis
Calcific aortic valve stenosis is the most com-
mon valvular heart disease in developed countries.
Its prevalence increases with age, and it affects 2–
–7% of the population over the age of 65 [1]. The
observed rise in the number of patients with severe
aortic stenosis (AS) in recent decades is related to
the significant increase in the average lifespan.
Calcific aortis stenosis is a gradually progres-
sive disease. During a long latent period, patients
remain asymptomatic. The progressive obstruction
in outflow and pressure overload is initially com-
pensated by myocardial hypertrophy without left
ventricle (LV) dilatation and normal systolic func-
tion is maintained. Once the degree of stenosis be-
comes severe, even slight changes in the aortic
valve area result in a larger rise in pressure gradi-
ent. An increase of oxygen consumption due to an
increase in systolic blood pressure in the LV,
ventricular mass and ejection time lead to myocar-
dial ischemia and deterioration of LV function. Fi-
nally, compensatory mechanisms fail and an imba-
lance between pump function and LV afterload oc-
curs (afterload mismatch). Ventricular chambers
dilate and ejection fraction decreases, and both ven-
tricular filling pressure and pulmonary pressure in-
crease. The onset of clinical symptoms is observed.
The development of angina, syncope or heart fail-
ure is a critical point, which leads to rapid deterio-
ration, resulting in a high mortality rate within
months (approx. 50% in the first two years after
symptoms appear) [2, 3]. Patients over the age of
70 have an even worse prognosis, with two- and
three-year survival rates of 37% and 25%, respec-
tively [4].
Without surgery, the prognosis is extremely
dismal. Therefore there is general agreement that
surgical aortic valve replacement (SAVR) should be
offered to patients with symptomatic severe aortic
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valve stenosis [1]. Surgery markedly improves
symptoms, physical functioning, quality of life and
prognosis. However, SAVR is denied to approx.
30–40% of elderly patients with severe, symptoma-
tic AS [1, 5–7]. Operative risk in SAVR is approx.
2–5% in patients under 70 years, and rises to 15%
in older adults with co-morbidities [1, 8–10]. Ac-
cording to Guidelines [1] though octogenarians and
nonagenarians experience higher perioperative
mortality and morbidity, advanced age should not
be a contraindication for surgery. Nevertheless, in
many reports, older age and LV dysfunction are the
most striking characteristics of patients, who were
denied surgery, whereas co-morbidities play a less
important role [5, 11].
Operative risk score calculators (i.e. Euro-
SCORE, STS score, ACEF) are used to determine
which patients are at a very high or prohibitive
surgical risk. However, many elderly patients are
deemed inoperable on the basis of co-morbidities
not included in surgical risk calculators, such as
chest radiation, porcelain aorta and frailty, liver
sclerosis, cirrhosis, debility, and nutritional status
[5, 9, 10, 12, 13]. Moreover, the STS-PROM score
appeared to underestimate mortality [9] and may
be unhelpful in identifying patients at high risk of
30-day death after transcatheter aortic valve implan-
tation (TAVI) [12]. In clinical practice, it seems rea-
sonable that high-risk patients should be evaluated
using clinical judgment and a combination of several
scores [9, 14]. Some authors have suggested that
since scores do not take into account some ‘extreme’
risk conditions that may be important in a transcath-
eter procedure, a new specific risk model for refer-
ring patients for TAVI should be established.
TAVI systems
Transcatheter aortic valve implantation is a novel
and effective procedure, introduced in 2002 by Alain
Cribier [15], which enables treatment of high-risk
patients who were denied surgery. Currently, two
different TAVI systems are commercially available:
Edwards SAPIEN (Edwards Life Sciences, Irvine,
CA, USA) and CoreValve ReValving System
(Medtronic Inc, Minneapolis, MN, USA).
The CoreValve ReValving System (Fig. 1) con-
sists of three porcine pericardial leaflets mounted
in a self-expandable nitinol frame housed within
a percutaneous delivery catheter. This system is
available in two sizes, 26 mm and 29 mm, for trans-
femoral or transaxillary/subclavian route. The frame
has three distinct functional levels with different
radial and hoop strengths. The upper third of the
frame, positioned within ascending aorta, has low
radial force and orients the prosthesis in the direc-
tion of the aortic root and blood flow. The valve lea-
flets are attached to the middle third of the frame;
supra-annular valve function delivers optimal hemo-
dynamics. The lower third of the frame, located
within the LV outflow tract, has high radial force
designed to prevent device migration. Intra-annu-
lar implantation and sealing skirt mitigates paraval-
vular leaks. The self-expandable nitinol frame en-
ables controlled release and partial repositionabili-
ty, and is designed to maintain coronary perfusion.
The 26 mm valve is deployed within a 55 mm stent,
and the 23 mm valve within a 53 mm stent. The
valve is introduced via an 18 F sheath.
The Edwards SAPIEN System (Fig. 2) consists
of three bovine pericardial leaflets mounted within
a tubular, slotted, stainless steel, balloon-expand-
able stent that is placed in the subcoronary posi-
tion. It is available in three sizes: 23, 26 and 29 mm
for transfermoral, transapical or transaxillary/sub-
clavian approach. The 23 mm valve is mounted in-
side a 14.5 mm long stent, and the 26 mm valve
within a 16 mm long stent. The greater part of the
stent is covered with a fabric skirt on its outer pe-
rimeter to prevent paravalvular leak. Bovine peri-
cardial leaflets are matched for thickness and elas-
ticity and incorporate Thermafix anti-calcification
treatment. The geometry and attachment method
Figure 1. The CoreValve ReValving System.
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of the leaflets have been designed to achieve a na-
turally closed shape and enhance valve durability
[16]. The 23 mm valve can be introduced via a 22 F
sheath, the 26 mm valve needs a 22 F to 24 F
sheath, and the 29 mm valve needs a 18 F to 19 F
sheath, depending on the type of catheter.
Several new models of prosthetic valves are
under evaluation.
Implantation approaches are the transfemoral
and transapical (the most widely used), and the tran-
saxillary/subclavian [17, 18] for patients with sig-
nificant iliofemoral disease.
The transfemoral approach is simpler and quick
to access the aortic valve. The aortic valve is
crossed and a stiff wire is placed in the LV with
a large loop. The native aortic valve is dilated us-
ing a valvuloplasty balloon with rapid pacing. The
prosthetic valve is advanced into position and the
native aortic valve is crossed. The device is de-
ployed once the satisfactory position is achieved
(Fig. 3). Transesophageal echocardiography and flu-
oroscopy are necessary for accurate positioning and
procedural guidance.
The transapical approach requires mini-thora-
cotomy. The apex of the heart is punctured using
a needle. The aortic valve is crossed antegradient-
ly, dilated, and stented under rapid pacing.
Advantages
Several studies have documented a dramatic
reduction in the left-aortic gradient and a marked
increase in the aortic valve area after the TAVI
procedure [12, 16, 19, 20]. Improvement in func-
tional class, quality of life and an enhanced distance
in the six-minute walk test have been reported [3,
21, 22] and seem to be permanent. A significant
decrease in brain natriuretic peptide has also been
observed [21].
The safety of the TAVI procedure is an impor-
tant consideration. Several studies and registries
have been introduced to evaluate mortality rates
and risk of the different TAVI systems and access-
es, and compare them with standard and surgical
therapy (Table 1). Several points are taken into con-
sideration: procedural success, 30-day and long-
-term mortality, and complications.
Procedural success is defined as the patient
leaving the procedure room with an implanted pros-
thesis without a major complication [13]. It was
assessed to be 75% in the initial experience of Cri-
bier et al. [23]. The success rate rises with increas-
Figure 2. The Edwards SAPIEN XT System.
Figure 3. Fluoroscopic images during transcatheter aortic valve (CoreValve) implantation; A. Balloon valvuloplasty;
B, C. Valve deployment in aortic position; D. Fluoroscopic aspect of the valve after deployment.
A B C D
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ing experience [16]. In the Edwards SAPIEN Aor-
tic Bioprosthesis European Outcome (SOURCE)
registry [30], the success rate was 93.8% and com-
parable to that of other contemporary series (93–
–98.5%), demonstrating the importance of training
and experience.
Similarly, the mortality rate was higher in ear-
ly reports [23], and has decreased as operators have
become more experienced. Nowadays the 30-day
survival rate ranges from 85–95% and a cumulative
one-year survival rate from 69–85% (Table 1).
These figures differ between the transfemoral and
the transapical in some analyses, which depend on
patients’ qualifying criteria to both approaches
(more diseased patients with severe atherosclero-
sis in the transapical group) [35]. The survival rate
is relatively low, but is primarily the consequence
of high preoperative risk and rarely due to the pro-
Table 1. Procedural outcome with TAVI in major studies and registries.
Study, year of publication Patients TAVI Approach Procedural 30 day Other
system success  mortality
I-REVIVE and RECAST 36 Edwards TF 75% 22.2% –
registries
Cribier et al. 2006 [23]
Lichtenstein et al. 2006 [24] 7 Edwards TA 100% 14% –
US registry 40 Edwards TA 88% 17.5% –
Svensson et al. 2008 [25]
Piazza et al. 2008 [26] 646 CoreValve TF 97% 8% –
Grube et al. 2008 [27] 136 CoreVlave TF/SC 70–91,2% Total: 12.5% Total one year
mortality 18.4%
Webb et al. 2009 [28] 168 Edwards TF/TA 94.1% Total: 11.3% One year
TF: 8% mortality 26%
TA: 18.2%
Bleiziffer et al. 2009 [29] 137 Edwards/ TF/SC/TA/ 98.5% 12.4% –
/CoreValve  /transaortic
SOURCE registry 1038 Edwards TF/TA 93.8% Total: 8.5% –
Thomas et al. 2010 [30] TF: 6.3%
TA: 10.3%
Rodés-Cabau et al. 2010 [12] 339 Edwards TF/TA 93,3% Total: 10.4% Mean eight
Canadian TF: 9.5% month follow-up
TA: 11.3%   22.1%
mortality rate
Petronio et al. 2010 [31] 514 CoreValve TF/SC TF: 98,4% TF: 6,4% –
SC: 100% SC: 0%
PARTNER trial 358 Edwards TF 96.6% 6.4% One year
Leon et al. 2010 [3]  (TAVI: 179, mortalty
standard 30.7%
therapy: 179)
FRANCE registry 244 Edwards/ TF/SC/TA 98.3% 12.7% –
Eltchaninoff et al. 2011 [32] /CoreValve
Belgian registry 328 Edwards/ TF/SC/TA 97% Total: 11% One year
Bosmans et al. 2011 [33] /CoreValve Edwards: 12%, mortality
CoreValve: 11% CoreValve
TF: 22%
CoreValve
SC: 0%
Edwards
TF: 18%
Edwards
TA: 37%
PARTNER EU 130 Edwards TF/TA TF: 96.4% TF: 8.2% –
Lefèvre et al. 2011 [20]  TA: 95.4%   TA: 18.8%
German registry 697 Edwards/ TF/SC/TA/ 98.4% 12.4% –
Zahn et al. 2011 [34]  /CoreValve  /transaortic
TF — transfemoral; SC — subclavian; TA — transapical
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cedure itself [33]. Mortality is related to the evolu-
tionary stage of disease and co-morbidities, as at-
tested by the predictive value of pulmonary hyper-
tension, severe mitral regurgitation (a three times
higher risk of death), post-procedural sepsis, chronic
kidney disease, chronic obstructive pulmonary di-
sease and the need for peri-procedural hemodynamic
support (a seven times higher risk of death) [12, 36].
Deaths occurring during late follow-up are mainly for
non-cardiac reasons [12]. It is worth noting that fac-
tors which influence survival after TAVI are also
prominent in patients undergoing SAVR [37–40].
Severe pulmonary hypertension is present
among one third of patients with severe AS and is
associated with end-stage AS, sudden clinical de-
terioration and sudden death [36]. The prognosis
for patients with AS with severe pulmonary hyper-
tension treated conservatively is poor. SAVR is as-
sociated with higher than usual mortality, however
the potential benefits outweigh the risk of surgery
[37]. The same probably applies to patients who un-
dergo TAVI.
Severe hemodynamic impairment is another
risk factor for SAVR, and this is an incentive to avoid
postponing any intervention until severe hemody-
namic impairment, which further increases the risk
of all procedures [36].
Functional mitral regurgitation might be ex-
pected to improve after TAVI because of the de-
crease in LV systolic pressure and delayed reverse
LV remodeling. Conversely, there is less likelihood
of observing an improvement in organic mitral re-
gurgitation [36]. Severe mitral regurgitation, as well
as severe pulmonary hypertension, may increase
a patient’s vulnerability during peri-procedural
hemodynamic changes and post-procedural compli-
cations [12].
Proper patient selection is crucial for proce-
dure success and increases procedure safety. Thus
patients with symptomatic severe AS who are con-
sidered inoperable, or at very high surgical risk, un-
dergo a systematic and precise workup protocol
including transthoracic and/or transesophageal
echocardiography, aortoiliofemoral and coronary
angiography and computed tomography. The current
indications and contraindications for TAVI are set out
in Table 2. According to the Al-Attar et al. report [35],
selection strategy (transapical vs transfemoral) is
crucial for outcome. Patients in the transapical group
had more co-morbidities and consequently a more
critical early post-operative period. The respective
places of transfemoral and transapical approaches
need to be clarified by a random study.
Patients who benefit from TAVI
There are several conditions which significant-
ly increase operative risk, and are acceptable in
TAVI procedure. We mention some of them below.
A patient with severe AS and reduced ejection
fraction has poor prognosis and despite high peri-
procedural risk, surgery is strongly recommended
[1]. However, the improvement in ejection fraction
varies among patients and apoptosis of a significant
proportion of cardiomyocytes induced during open-
heart surgery may compromise post-operative re-
covery of myocardial function [41]. Clavel et al. [41]
compared 200 patients undergoing SAVR with 83 pa-
tients undergoing TAVI for severe AS with reduced
LV systolic function (left ventricular ejection frac-
tion [LVEF] £ 50%). Despite similar baseline LVEF
(34 ± 11% vs 34 ± 10%), the TAVI patients had
faster and better recovery of LVEF compared with
SAVR patients and better regression of LV dilata-
Table 2. Indications and contraindications for TAVI.
Indications for TAVI Contraindications for TAVI
Severe symptomatic aortic stenosis in elderly — Aortic annulus diameter < 18 mm or > 25 mm for
patients at high risk with logistic EuroSCORE balloon expandable and < 20 or > 27 for self
> 20 and STS score > 10 or with contraindications expandable devices
for surgery (such as prior chest radiation, previous — Ascending aorta diameter > 43 mm
aorto-coronary bypass with patent grafts, porcelain — Severe organic mitral regurgitation
aorta, liver cirrhosis, severe chest deformities) — LVEF < 20% without contractile reserve
— Atrial or ventricular thrombus
— Sub-aortic stenosis
— Recent myocardial infarction and cerebrovascular event
— Life expectancy < 12 months
— For vascular access — vascular diameter < 6 mm
or severe ilio-femoral stenosis
LVEF — left ventricular ejection fraction
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tion at discharge and one-year follow up. At the one-
year follow-up, 58% of TAVI patients had a norma-
lization of LVEF, as opposed to 20% in the SAVR
group. Thus TAVI may provide an interesting al-
ternative to SAVR in patients with depressed LV
systolic function considered to be at high surgical
risk. The greater increase in LVEF in the TAVI
group may be due to the better improvement in
aortic valve hemodynamics (i.e. aortic valve area
and gradient), and a more complete relief of the
valvular obstruction and thereby of the pressure
overload imposed on the LV compared with SAVR.
Porcelain aorta is defined as an extensive cir-
cumferential calcification of the thoracic aorta as
assessed by computed tomography or fluoroscopy
[12]. If this condition is present, the ascending aor-
ta cannot be safely clamped and patients are often
refused surgery. In the analysis by Rodés-Cabau et
al. [12], patients diagnosed with porcelain aorta or
frailty had similar 30-day and late results compared
with the rest of the study population. Periprocedural
stroke rate was relatively low (1.6%), and 30-day
mortality was similar to that of the rest of the study
group, which may indicate high risk of these pa-
tients even though STS-PROM score was lower.
Those who survived the procedure tended to have
a lower risk of death at one-year follow-up.
A promising indication for the use of a TAVI
system is interventional treatment of a degenerat-
ed bioprosthesis. In elderly patients, a bioprosthetic
device is usually the valve of choice, to avoid the
need for anticoagulation with its associated compli-
cations. The success of surgical treatment prolongs
the lifespan of patients with AS, therefore cases of
degenerated valves may be anticipated. Additio-
nally, in parallel with the increasing age of patients
operated on due to valve disease, the amount and
severity of co-morbidities are increasing steadily
[42, 43]. Management of these patients remains
a challenge because of the higher surgical risk of
repeat SAVR [43]. As a consequence, TAVI as an
alternative approach to a re-thoracotomy is likely
to be of help to such patients [42]. The ‘valve-in-
-valve’ procedures have been performed by several
surgeons with favorable hemodynamic and clinical
results [17, 42–44].
The TAVI system has also been employed in
several cases of patients with co-morbidities or
conditions which are very rarely encountered and
therefore are an extremely difficult challenge for
many medical specialties. Among them are patients
with severe aortic stenosis with severe spinal de-
formities, e.g. extremely severe kyphoscoliosis and
thorax deformation in the course of Pott’s disease
[45], or heart transplant recipients who need im-
provement of allograft function long after heart
transplantation [46, 47].
Disadvantages
TAVI is an interventional procedure, and is
therefore not free from risk of complications. The
incidence also depends on the operator’s experience
and access choice (transfemoral vs transapical). The
most common complications are described below.
Large femoral access sheaths used to insert
a TAVI system (18–24 F sheaths) contribute to the
frequent occurrence of major vascular complications
and bleeding events (5–16%) [2, 3]. In the SOURCE
registry, 10.6% of patients had major vascular com-
plications, although they had no impact on 30-day
mortality. Major vascular complications were less
frequent in the transapical-approach group (2.4%).
However when vascular complications occurred in
the transapical group, the mortality was very high,
although the nature of the vascular complications
was not defined [13].
According to Bagur at al. [48], the occurrence
of acute kidney injury following TAVI is associated
with a greater than four-fold increase in the risk of
post-operative mortality. However, the incidence
of acute kidney injury was lower (p = 0.001) in pa-
tients with chronic kidney disease who underwent
TAVI compared with those who underwent SAVR.
Potential causes of renal failure are intraprocedu-
ral hypotension, contrast load, number of blood
transfusions, post-interventional thrombocytope-
nia, severe inflammatory response syndrome and
concomitant medication [13, 49].
Strokes remain a troublesome adverse event
following TAVI. According to recent studies [50, 51]
conducted with the use of magnetic resonance
imaging, there are new perfusion deficits due to
atherothrombotic emboli in 58–91% of patients who
undergo TAVI. This observation does not appear
to correlate with clinical neurological deficits. The
PARTNER investigators [3] observed major
strokes in 5% of patients and the SOURCE investi-
gators [30] in 2.5% of patients. Emerging emboli
prevention devices might provide better protection
of the brain during TAVI. Empiric oral therapy with
aspirin and clopidogrel for three to six months af-
ter procedure, followed by long-term aspirin, is re-
commended.
Residual aortic regurgitation, mainly in the
form of paravalvular leaks, is a frequent complica-
tion [35]. However, even moderate aortic regurgi-
tation appears to be well tolerated without heart
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failure or hemolysis, and usually remains stable
during the one-year follow-up period [3, 13, 52]. In
severe regurgitation, valve-in-valve implantation
has been described [53]. Excluding patients with an
annulus larger than recommended prostheses is
prudent to avoid significant regurgitation [52].
High-grade atrio-ventricular block and consec-
utive pacemaker implantation are frequent compli-
cations following TAVI and persist in follow-up [54].
Conduction tissue impairment is probably provoked
by mechanical compression with large prostheses
in smaller annuli or in the larger area of the Core-
Valve covering the outflow tract, and may appear
instantly during the implantation procedure [52, 55].
Continuous post-operative electrocardiogram mo-
nitoring is necessary for at least 2–3 days in all pa-
tients after TAVI, and until discharge in patients
with increased risk for this complication. Permanent
pacemaker implantation is necessary in 18–40% of
patients [56], more commonly with CoreValve sys-
tem. The need for a pacemaker is less than 10% in
SAVR [56].
Coronary artery obstruction and/or myocardial
infarction during or after procedure occur in 0.4–
–4.1% of patients [30, 57] and in some cases may
require immediate coronary angioplasty [57, 58].
Other, less common, complications or prob-
lems concerning the TAVI procedure are pericar-
dial tamponade, valve migration or fracture, need
for conversion to surgery, and re-intervention.
Summary
The results of several studies and registries
suggest that TAVI may be a good alternative for
elderly patients who are not suitable candidates for
surgery. Certainly, there are patients still disquali-
fied from any invasive therapy. Hopefully, further
improvements in TAVI technique might facilitate
the procedure in this ‘problematic’ group of patients.
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